Innovent's IBI343 Meets Dual Primary Endpoints in Phase 3 Gastric Cancer Trial
Start here
At the 2026 ESMO congress, Innovent announced in a late-breaking abstract that the international, multicenter phase 3 G-HOPE-001 study of IBI343, a CLDN18.2-directed antibody-drug conjugate, met both of its primary endpoints in gastric cancer: progression-free survival and overall survival. The results mark a positive readout for the candidate in a disease setting where CLDN18.2 has emerged as a key target. Full trial data, including the magnitude of the survival benefit, safety profile and regulatory filing plans, have yet to be presented in detail or disclosed beyond the topline endpoint achievement.
Written by a model from the reports · updated 4 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- mp.weixin.qq.comPickESMO G-HOPE-001 Interim Analysis: Arcotatug Tavatecan Median PFS 7.1 Months in Later-Line CLDN18.2-Positive Gastric Cancer
The ESMO 2026 LBA77 interim analysis of the phase 3 G-HOPE-001 trial in later-line CLDN18.2-positive gastric cancer showed arcotatug tavatecan met both co-primary endpoints of PFS and OS. At IA2, median PFS was 7.1 vs 3.1 months, HR 0.45 (95% CI 0.35-0.58); median OS was 10.2 vs 6.9 months, HR 0.57 (95% CI 0.45-0.73); confirmed ORR was 37.4% vs 7.7%.
- mp.weixin.qq.comInnovent Announces at 2026 ESMO LBA That IBI343 Met PFS and OS Dual Primary Endpoints in Phase 3 G-HOPE-001 Gastric Cancer Study
At the 2026 ESMO congress, Innovent announced in a late-breaking abstract that the international multicenter phase 3 G-HOPE-001 study of the CLDN18.2 ADC IBI343 in gastric cancer met both primary endpoints of progression-free survival and overall survival.
Heat trend for this story
Heat now 8·Peak in the comparable set 10 (Oct 23 21:00)·Change over 24h in the comparable set –·Participants now 1
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.